Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.41 - $1.24 $111,132 - $336,109
-271,056 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$0.62 - $1.17 $14,818 - $27,963
-23,900 Reduced 8.1%
271,056 $177,000
Q4 2021

Feb 15, 2022

BUY
$1.09 - $1.89 $6,936 - $12,027
6,364 Added 2.21%
294,956 $322,000
Q3 2021

Nov 15, 2021

SELL
$1.44 - $2.73 $586 - $1,111
-407 Reduced 0.14%
288,592 $525,000
Q2 2021

Aug 16, 2021

SELL
$2.63 - $3.67 $85,759 - $119,671
-32,608 Reduced 10.14%
288,999 $763,000
Q3 2020

Nov 17, 2020

BUY
$2.39 - $3.43 $449 - $644
188 Added 0.06%
321,607 $810,000
Q2 2020

Aug 17, 2020

BUY
$2.2 - $3.71 $87,907 - $148,244
39,958 Added 14.2%
321,419 $1.05 Million
Q1 2020

May 13, 2020

BUY
$1.9 - $4.98 $68,951 - $180,724
36,290 Added 14.8%
281,461 $690,000
Q4 2019

Feb 14, 2020

SELL
$3.95 - $5.35 $19,564 - $26,498
-4,953 Reduced 1.98%
245,171 $1.16 Million
Q3 2019

Nov 15, 2019

BUY
$4.13 - $6.94 $12,340 - $20,736
2,988 Added 1.21%
250,124 $1.07 Million
Q2 2019

Aug 14, 2019

BUY
$3.98 - $6.2 $181,810 - $283,222
45,681 Added 22.68%
247,136 $1.44 Million
Q1 2019

May 09, 2019

SELL
$2.0 - $4.4 $11,424 - $25,132
-5,712 Reduced 2.76%
201,455 $776,000
Q4 2018

Feb 13, 2019

BUY
$1.61 - $3.62 $7,203 - $16,195
4,474 Added 2.21%
207,167 $387,000
Q3 2018

Nov 14, 2018

BUY
$2.26 - $3.27 $3,008 - $4,352
1,331 Added 0.66%
202,693 $649,000
Q2 2018

Aug 14, 2018

BUY
$3.02 - $4.94 $3,805 - $6,224
1,260 Added 0.63%
201,362 $608,000
Q1 2018

May 15, 2018

SELL
$3.46 - $5.14 $24,271 - $36,057
-7,015 Reduced 3.39%
200,102 $784,000
Q4 2017

Feb 14, 2018

SELL
$4.0 - $6.54 $8,140 - $13,308
-2,035 Reduced 0.97%
207,117 $857,000
Q3 2017

Nov 13, 2017

BUY
$4.99 - $6.57 $1.04 Million - $1.37 Million
209,152
209,152 $1.28 Million

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $443M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.